Christian & Timbers is pleased to announce that Telix Pharmaceuticals has appointed Maria Rivas, MD as a Non-Executive Director, effective May 11, 2026. The appointment strengthens the Telix Board's capabilities in clinical leadership, late-stage development, and public company governance.
Dr. Rivas brings more than 25 years of experience across oncology, rare diseases, and neuroscience, with a career built on developing and commercializing medical devices and pharmaceutical products at the highest level of the industry. She served most recently as Chief Medical Officer at Pfizer, Inc. (NYSE: PFE), one of the world's largest pharmaceutical companies, where she oversaw global operations spanning thousands of data scientists, healthcare experts, and field staff, and led the launch of multiple blockbuster medical products.
She currently serves on the Board of The Cooper Companies, Inc. (NASDAQ: COO) and previously served as an independent Director at Medidata (NASDAQ: MDSO) through its successful merger with Dassault Systèmes. Dr. Rivas holds a B.A. in Biochemistry from Brandeis University and an MD from Columbia University's Vagelos College of Physicians and Surgeons, and completed her fellowship in Endocrinology at New York-Presbyterian Hospital.
Telix Pharmaceuticals is a commercial-stage biopharmaceutical company at the forefront of radiopharmaceuticals for targeted cancer diagnostics and therapy. The company closed FY 2025 with US$804 million in revenue, is targeting US$950 to $970 million in 2026, and has three pivotal-stage trials underway across prostate, kidney, and brain cancer.
Dr. Rivas's depth in clinical development and governance brings the Telix Board exactly the expertise required as the company advances its therapeutic pipeline and expands its global footprint. Congratulations to Dr. Rivas and the Telix leadership team on this appointment.